Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
287 results about "Neurologic disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A neurological disease is a disorder that affects the body’s nervous system. Over six hundred conditions fall under the category of neurological disease. ... Degenerative neurological diseases are common, too. Parkinson’s disease and Alzheimer’s disease are both caused by nerve cells that have become damaged and died.
Augmented reality display system for evaluation and modification of neurological conditions, including visual processing and perception conditions
ActiveUS20170365101A1Increase alertnessImprove plasticityMedical automated diagnosisMental therapiesWavefrontPattern perception
In some embodiments, a display system comprising a head-mountable, augmented reality display is configured to perform a neurological analysis and to provide a perception aid based on an environmental trigger associated with the neurological condition. Performing the neurological analysis may include determining a reaction to a stimulus by receiving data from the one or more inwardly-directed sensors; and identifying a neurological condition associated with the reaction. In some embodiments, the perception aid may include a reminder, an alert, or virtual content that changes a property, e.g. a color, of a real object. The augmented reality display may be configured to display virtual content by outputting light with variable wavefront divergence, and to provide an accommodation-vergence mismatch of less than 0.5 diopters, including less than 0.25 diopters.
Owner:MAGIC LEAP
1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00001.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00002.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00003.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
Owner:BIOSPLICE THERAPEUTICS INC
Modulators of dopamine neurotransmission
InactiveUS6903120B2Good effectImproved pharmacokinetic propertiesBiocideNervous disorderPharmaceutical drugDouble bond
New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms
The disclosed embodiments provide a method for acquiring MR data at resolutions down to tens of microns for application in in vivo diagnosis and monitoring of pathology for which changes in fine tissue textures can be used as markers of disease onset and progression. Bone diseases, tumors, neurologic diseases, and diseases involving fibrotic growth and / or destruction are all target pathologies. Further the technique can be used in any biologic or physical system for which very high-resolution characterization of fine scale morphology is needed. The method provides rapid acquisition of signal at selected values in k-space, with multiple successive acquisitions at individual k-values taken on a time scale on the order of microseconds, within a defined tissue volume, and subsequent combination of the multiple measurements in such a way as to maximize SNR. The reduced acquisition volume, and acquisition of only signal values at select places in k-space, along selected directions, enables much higher in vivo resolution than is obtainable with current MRI techniques.
Owner:BIOPROTONICS
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases.
Owner:MASSACHUSETTS INST OF TECH
Variational parameter neurostimulation paradigm for treatment of neurologic disease
InactiveUS20080243204A1Good curative effectElectrotherapyArtificial respirationNervous systemHabituation
The present invention concerns a neural stimulation device, and methods for its use, in which one or more stimulation parameters can be automatically and randomly adjusted such that any particular combination of stimulation parameters is not repeated for a given duration of time, thereby limiting habituation to the neural stimulus.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Dock-and-lock (DNL) complexes for delivery of interference RNA
ActiveUS8491914B2Efficient deliveryHighly selective and specific deliveryNervous disorderAntipyreticDendrimerAutoimmune disease
Owner:IBC PHARMACEUTICALS INC
Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists
InactiveUS20050119285A1Reducing REM sleepTreating and preventing neurological disordersBiocideNervous disorderRapid Eye MovementsNeurological disorder
This invention relates to a method for treating and preventing neurological disorders related to rapid-eye-movement (REM) sleep disturbances in a mammal comprising administering to the mammal an amount of an NPY Y5 receptor antagonist which effectively reduces REM sleep.
Owner:PFIZER INC
Methods and Compositions for Diagnosing, Prognosing, and Treating Neurological Conditions
ActiveUS20140162933A1Decreased CI activityShorten the lengthCompound screeningApoptosis detectionNervous systemPhysiology
This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.
Owner:POPULATION BIO INC
Monoclonal antibody
ActiveUS20070166311A1Retaining and increasing cognitive memory capacityReduce amyloid burdenSenses disorderNervous disorderΒ amyloid proteinNervous system
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
Owner:AC IMMUNE SA
HDAC inhibitors and therapeutic methods using the same
ActiveUS9249087B2High sensitivityDegree of isoform selectivity for an HDACIOrganic active ingredientsOrganic chemistryAutoimmune diseaseMalaria
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA +1
Transcutaneous electrical stimulation for treating neurological disorders
Owner:BOSTON SCI NEUROMODULATION CORP
Apparatus for management of a parkinson's disease patient's gait
ActiveUS20180140842A1Relieve and prevent gait abnormalityAvoid exceptionElectrotherapyWalking aidsDisease patientBiological activation
A gait management apparatus applies stimulation to a user suffering from a neurological disease (such as Parkinson's Disease) gait dysfunction. Motion sensors are arranged to be worn by a patient, and electrical stimulation electrodes are on the legs for stimulation. A controller receives motion sensing signals, and processes these signals to generate stimulation signals for operation of the electrodes to stimulate limb movement upon detection of a gait abnormality. There may be a user actuator for user actuation of electrical stimulation, and the inputs may be a series of taps. The controller may provide signals to prevent occurrence of freezing of gait when it senses that a patient is walking or has an intention to walk. Also, it may apply stimulation at an intensity level which is insufficient for functional muscle stimulation but sufficiently high to trigger activation of efferent nerves.
Owner:NATIONAL UNIVERSITY OF IRELAND
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Systems and methods for tissue stimulation in medical treatment
ActiveUS8788044B2Reduce morbidityReduce the amount requiredHead electrodesFlow monitorsMedical disorderFrequency spectrum
Stimulation treatments for various medical disorders, such as neurological disorders, comprise novel systems, strategies, and methods for providing TMS, electrical, magnetic, optical and other stimulation. Some stimulation methods comprise varying the stimulation parameters to improve the therapeutic efficacy of stimulation, and decrease risk of habituation and side-effects such as interference with normal brain, sensory, motor, and cognitive processes. The creation, and subsequent variation, of stimulation parameters can use sensed data in order to match, adjust, or avoid matching characteristics of the stimulation therapy relative to certain endogenous brain activities. Novel methods are described for choosing, creating and subsequently stimulating with partial signals which summate to produce therapeutic vector fields having unique temporal patterns and low-or high-frequency spectral content.
Owner:JOHN MICHAEL SASHA
Cyclosporin a conjugates and uses therefor
InactiveUS6316405B1Highly effective to treat or prevent neurological disordersAct synergisticallyNervous disorderMetabolism disorderAmyotrophic lateral sclerosisAmyloid
Disclosed are conjugates of Abeta-binding peptides and CsA analogs and conjugates of Abeta-binding peptides and FK506 Binding Peptide inhibitors. These conjugates chemically induce dimerization of either cyclophilin or FK506 Binding Peptide with Abeta peptide, a major component of amyloid plaques found in neurological disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The conjugates are useful in the treatment of neurological diseases involving the formation of amyloid plaques because they inhibit and / or prevent the aggregation and deposition of Abeta peptide into plaques.
Owner:WISCONSIN ALUMNI RES FOUND
Method for detection of a neurological disease
InactiveUS20140086836A1Simple methodDelay disease progressionPeptide librariesIn-vivo radioactive preparationsAmyloidOrganism
The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).
Owner:COMMONWEALTH SCI & IND RES ORG +3
Animal model simulating neurologic disease
InactiveUS20050102708A1Compounds screening/testingPeptide/protein ingredientsPharmacometricsButhionine sulfoximine
The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.
Owner:SAMARITAN PHARMA +1
Modulators of dopamine neurotransmission
InactiveUSRE46117E1Good effectImproved pharmacokinetic propertiesOrganic chemistryDouble bondDopamine neurotransmission
New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed
Owner:PRILENIA NEUROTHERAPEUTICS LTD
Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.
Owner:YEDA RES & DEV CO LTD
Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms
The disclosed embodiments provide a method for acquiring MR data at resolutions down to tens of microns for application in in-vivo diagnosis and monitoring of pathology for which changes in fine tissue textures can be used as markers of disease onset and progression. Bone diseases, tumors, neurologic diseases, and diseases involving fibrotic growth and / or destruction are all target pathologies. Further the technique can be used in any biologic or physical system for which very high-resolution characterization of fine scale morphology is needed. The method provides rapid acquisition of selected values in k-space, with multiple successive acquisitions of individual k-values taken on a time scale on the order of microseconds, within a defined tissue volume, and subsequent combination of the multiple measurements in such a way as to maximize SNR. The reduced acquisition volume, and acquisition of only select values in k-space along selected directions, enables much higher in-vivo resolution than is obtainable with current MRI techniques.
Owner:BIOPROTONICS
Neuorological condition detection unit and method of using the same
ActiveUS20160287127A1Quick placementEasy to placeElectroencephalographySensorsNeurologic statusNerve condition
A neurological condition detection unit can include a computer device that is connected to at least two leads that are connectable to a patient for evoking a response from that patient via an electrical current passed through the leads (e.g. a shock) and at plurality of sensors connected to the computer device to sense how the left side and right side of the patient's brain reacts to the evoked event (e.g. the shock). The stroke detection device and / or neurological condition detection unit can be configured to output a warning when one side of the patient's brain is determined to react differently than the opposite side of the patient's brain by at least a pre-selected threshold value. The warning can include an identification of a nearby care facility that may be best suited for providing care to a patient determined to have a neurological condition (e.g. a stroke).
Owner:FOREST DEVICES INC
Histone deacetylase inhibitors as therapeutics for neurological diseases
InactiveUS20070219244A1Increasing frataxin mRNANormal function of geneBiocideNervous disorderMedicineHDAC inhibitor
Owner:THE SCRIPPS RES INST
NGF-Fc fusion protein and preparation method thereof
InactiveCN105273087AImprove stabilityExtended half-lifeNervous disorderPeptide/protein ingredientsDiseaseNervous system
The invention belongs to the technical field of biological engineering, and relates to an NGF-Fc fusion protein and a preparation method thereof. The method comprises the following steps: constructing a human immune globulin IgG Fc and nerve growth factor (NGF) fusion gene expression vector through a genetic engineering means, transferring to a mammal cell to make the transferred mammal cell highly express and produce NGF-Fc fusion proteins, purifying, identifying and carrying out biological activity detection. The expression vector transferred mammal cell constructed in the invention can express bioactive NGF-Fc fusion proteins, so the expression level can be 150mg / L or above, and the obtained protein has good stability and long half life, and can be used to prepare drugs for treating Alzheimer's disease, diabetic peripheral neuropathy, Parkinson's disease, facial neuritis, craniocerebral trauma, trauma of spinal cord, acute cerebrovascular disease, encephalatrophy and other neurological diseases, and peripheral nerve injury acute cerebral vascular central nerve injuries induced by chemical drugs.
Owner:FUDAN UNIV
Use of GLP-1 Analogues for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission
The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age.
Owner:INNOVATION ULSTER LTD
Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
InactiveUS20050048606A1High resolutionNon invasivePeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsGene deliveryNeurotrophin Receptor p75
The invention provides a novel recombinant polypeptide that comprises a nucleic acid binding element and a hairpin motif that selectively binds to a neurotrophin receptor. The recombinant polypeptide may be used for neurotrophin receptor mediated delivery of nucleic acid, including therapeutic DNA, bound to the recombinant polypeptide. In one embodiment, the hairpin motif is a hairpin motif of a neurotrophin, such as nerve growth factor, brain derived neurotrophic factor, neurotrophin 3 and neurotrophin 4 / 5. The hairpin motif is also a neurotrophin agonist and therefore may be used to treat any disorder responsive to neurotrophin treatment, such as neurological disorders and tumour. In one embodiment the agonist comprises a hairpin motif that selectively binds to a neurotrophin receptor and a positively charged binding domain which is believed to enhance receptor binding by binding to negatively charged cell membrane.
Owner:AGENCY FOR SCI TECH & RES
Drug for nerve regeneration
InactiveUS20060217368A1Increase the number ofBiocideNervous disorderNervous systemManic-depressive psychoses
An object of the present invention is to provide a nerve regenerating drug, an agent for the promotion of neuropoiesis of a neural stem cell, a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis, and a method of the manufacture of the neuron. In order to achieve the object, the invention provides a nerve regenerating drug comprising a substance that inhibits the activity of glycogen synthase kinase-3, as an active ingredient; an agent for the promotion of neuropoiesis of a neural stem cell comprising the substance as an active ingredient; a neuron obtained by culturing a neural stem cell in the presence of the agent for the promotion of neuropoiesis; and a method of the manufacture of the neuron. The medical drug according to the invention is useful as a therapeutic drug for neurological diseases such as Parkinson's disease, Alzheimer's disease, Down's disease, cerebrovascular disorder, cerebral stroke, spinal cord injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, anxiety disorder, schizophrenia, depression and manic depressive psychosis.
Owner:KYOWA HAKKO KOGYO CO LTD
Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA
ActiveUS20110123436A1Efficient deliveryHighly selective and specific deliveryNervous disorderAntibody mimetics/scaffoldsDendrimerAutoimmune responses
Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.
Owner:IBC PHARMACEUTICALS INC
Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
ActiveUS20120252693A1Improve efficiencySensitive highNucleotide librariesMicrobiological testing/measurementSynapseNervous system
Owner:DIAMIR
Selective sampling magnetic resonance-based method for assessing structural spatial frequencies
The disclosed embodiments provide a method for acquiring MR data at resolutions down to tens of microns for application in in-vivo diagnosis and monitoring of pathology for which changes in fine tissue textures can be used as markers of disease onset and progression. Bone diseases, tumors, neurologic diseases, and diseases involving fibrotic growth and / or destruction are all target pathologies. Further the technique can be used in any biologic or physical system for which very high-resolution characterization of fine scale morphology is needed. The method provides rapid acquisition of selected values in k-space, with multiple successive acquisitions of individual k-values taken on a time scale on the order of microseconds, within a defined tissue volume, and subsequent combination of the multiple measurements in such a way as to maximize SNR. The reduced acquisition volume, and acquisition of only select values in k-space along selected directions, enables much higher in-vivo resolution than is obtainable with current MRI techniques.
Owner:BIOPROTONICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com